Personal tools

DOID:14566

From FANTOM5_SSTAR

Jump to: navigation, search

Name:disease of cellular proliferation
Namespace:FANTOM
Definition:"A disease that is characterized by abnormally rapid cell division." [url:http://en.wikipedia.org/w/index.php?title
Synonyms: "cell process disease" EXACT []
Alt_id: DOID:0000818

Ontology association<br>Each term has an is_a parent in the Disease Ontology, which has a linkage to an another entity and FANTOM5 samples.Libraries were grouped into mutually exclusive facets according to the FANTOM5 sample ontology mapping to DISEASE ontologies.<br><br>link to ontology dataset<br>data

Parents

is_a:DOID:4(disease)



Children


is a:DOID:0060072 (benign neoplasm),DOID:162 (cancer)

Ontology Tree: Loaded from BioPortal

Ontorolgy tree(Small window open)

FF samples

Human (Homo sapiens)

  • 10399-106A3 (acute myeloid leukemia (FAB M5) cell line:THP-1 (fresh))
  • 10400-106A4 (acute myeloid leukemia (FAB M5) cell line:THP-1 (revived))
  • 10405-106A9 (acute myeloid leukemia (FAB M5) cell line:THP-1 (thawed))
  • 10408-106B3 (lung adenocarcinoma cell line:PC-14)
  • 10409-106B4 (chronic myelogenous leukemia cell line:KU812)
  • 10410-106B5 (extraskeletal myxoid chondrosarcoma cell line:H-EMC-SS)
  • 10411-106B6 (renal cell carcinoma cell line:OS-RC-2)
  • 10412-106B7 (malignant trichilemmal cyst cell line:DJM-1)
  • 10413-106B8 (glioma cell line:GI-1)
  • 10414-106B9 (maxillary sinus tumor cell line:HSQ-89)

... further results Mouse (Mus musculus)

  • 10399-106A3 (acute myeloid leukemia (FAB M5) cell line:THP-1 (fresh))
  • 10400-106A4 (acute myeloid leukemia (FAB M5) cell line:THP-1 (revived))
  • 10405-106A9 (acute myeloid leukemia (FAB M5) cell line:THP-1 (thawed))
  • 10408-106B3 (lung adenocarcinoma cell line:PC-14)
  • 10409-106B4 (chronic myelogenous leukemia cell line:KU812)
  • 10410-106B5 (extraskeletal myxoid chondrosarcoma cell line:H-EMC-SS)
  • 10411-106B6 (renal cell carcinoma cell line:OS-RC-2)
  • 10412-106B7 (malignant trichilemmal cyst cell line:DJM-1)
  • 10413-106B8 (glioma cell line:GI-1)
  • 10414-106B9 (maxillary sinus tumor cell line:HSQ-89)

... further results

Enrichment analysis: top 100 FFCP enriched with this ontology termTOP 100 FANTOM5 Cage Peaks enriched with DOID:14566 (disease of cellular proliferation), sorted by p-values <br>Analyst: Hideya Kawaji<br><br>link to source dataset <br>human : data <br>mouse : data

P-valueFFCPShort description
1.11e-77FFCP PHASE2:Hg19::chrX:153991088..153991168,+#_a069a9edb8a377d70919f7a15e49ddd6p1@DKC1
1.11e-77FFCP PHASE1:Hg19::chrX:153991088..153991168,+#_a069a9edb8a377d70919f7a15e49ddd6p1@DKC1
4.12e-73FFCP PHASE2:Hg19::chr11:1372935..1372952,+#_4e81f74e33f1aed7a98394b0daae6044p@chr11:1372935..1372952, +
4.12e-73FFCP PHASE1:Hg19::chr11:1372935..1372952,+#_4e81f74e33f1aed7a98394b0daae6044p@chr11:1372935..1372952, +
7.94e-66FFCP PHASE2:Hg19::chr2:197504410..197504471,+#_6e45ddc3676cc3452476b3211bc5749cp1@CCDC150
7.94e-66FFCP PHASE1:Hg19::chr2:197504410..197504471,+#_6e45ddc3676cc3452476b3211bc5749cp1@CCDC150
8.26e-65FFCP PHASE1:Hg19::chr17:38444115..38444194,+#_164d2f7f2cb166c50db4781f26756a77p1@CDC6
8.26e-65FFCP PHASE2:Hg19::chr17:38444115..38444194,+#_164d2f7f2cb166c50db4781f26756a77p1@CDC6
2.36e-64FFCP PHASE2:Hg19::chr17:41277372..41277418,-#_841fd575e01a3b52e3c3a67dc1d89cb5p1@BRCA1
2.36e-64FFCP PHASE1:Hg19::chr17:41277372..41277418,-#_841fd575e01a3b52e3c3a67dc1d89cb5p1@BRCA1
6.38e-64FFCP PHASE1:Hg19::chrX:153991175..153991226,+#_1cb476246f8db081b6c140351fb1eb4ep2@DKC1
6.38e-64FFCP PHASE2:Hg19::chrX:153991175..153991226,+#_1cb476246f8db081b6c140351fb1eb4ep2@DKC1
1.3e-63FFCP PHASE2:Hg19::chr20:57617831..57617909,-#_64b7f815413b36a8c409d99bd10de946p1@SLMO2
1.3e-63FFCP PHASE1:Hg19::chr20:57617831..57617909,-#_64b7f815413b36a8c409d99bd10de946p1@SLMO2
3.85e-63FFCP PHASE1:Hg19::chr1:214776516..214776565,+#_82e117f810e745ec6abfcf1dc89e4491p1@CENPF
3.85e-63FFCP PHASE2:Hg19::chr1:214776516..214776565,+#_82e117f810e745ec6abfcf1dc89e4491p1@CENPF
7.33e-63FFCP PHASE2:Hg19::chr2:198364552..198364576,-#_11ecfa860f54fd992c18a89591fa6276p1@HSPD1
7.33e-63FFCP PHASE1:Hg19::chr2:198364552..198364576,-#_11ecfa860f54fd992c18a89591fa6276p1@HSPD1
1.04e-62FFCP PHASE2:Hg19::chr7:56119449..56119492,+#_8772def32e6ef50ea8c4d9289cb9796dp1@CCT6A
1.04e-62FFCP PHASE1:Hg19::chr7:56119449..56119492,+#_8772def32e6ef50ea8c4d9289cb9796dp1@CCT6A
1.45e-62FFCP PHASE2:Hg19::chr8:124408630..124408647,-#_3f613050903461e86c69f38ea5321b68p2@ATAD2
1.45e-62FFCP PHASE1:Hg19::chr8:124408630..124408647,-#_3f613050903461e86c69f38ea5321b68p2@ATAD2
1.65e-62FFCP PHASE2:Hg19::chr1:154947126..154947147,+#_8848bd404d49272423441104d0ba3334p2@CKS1B
1.65e-62FFCP PHASE1:Hg19::chr1:154947126..154947147,+#_8848bd404d49272423441104d0ba3334p2@CKS1B
4.1e-62FFCP PHASE2:Hg19::chr1:214776570..214776593,+#_4ce1635fbc63873a924f428eb99a590cp2@CENPF
4.1e-62FFCP PHASE1:Hg19::chr1:214776570..214776593,+#_4ce1635fbc63873a924f428eb99a590cp2@CENPF
7.02e-62FFCP PHASE1:Hg19::chr3:179280702..179280769,+#_92f5450b66a179bf72e794994773f4fcp1@ACTL6A
7.02e-62FFCP PHASE2:Hg19::chr3:179280702..179280769,+#_92f5450b66a179bf72e794994773f4fcp1@ACTL6A
7.23e-62FFCP PHASE1:Hg19::chr1:154947148..154947175,+#_a8180e5af452ae44a4e6215ac1e22d39p1@CKS1B
7.23e-62FFCP PHASE2:Hg19::chr1:154947148..154947175,+#_a8180e5af452ae44a4e6215ac1e22d39p1@CKS1B
1.53e-61FFCP PHASE1:Hg19::chr4:57301645..57301675,-#_d5d9b8ed7dfc2143c3597c887420eda2p2@PPAT
1.53e-61FFCP PHASE2:Hg19::chr4:57301645..57301675,-#_d5d9b8ed7dfc2143c3597c887420eda2p2@PPAT
1.96e-61FFCP PHASE2:Hg19::chr7:105162652..105162709,-#_86ff9cdddf579e246fad466840dad718p1@PUS7
1.96e-61FFCP PHASE1:Hg19::chr7:105162652..105162709,-#_86ff9cdddf579e246fad466840dad718p1@PUS7
3.33e-61FFCP PHASE2:Hg19::chr17:38574169..38574180,-#_14e3b1825f5fd31470f4dd9e483d5affp2@TOP2A
3.33e-61FFCP PHASE1:Hg19::chr17:38574169..38574180,-#_14e3b1825f5fd31470f4dd9e483d5affp2@TOP2A
4.29e-61FFCP PHASE2:Hg19::chr1:211848955..211848981,-#_55ebf954411c5e3590431e6c5718d42ep1@NEK2
4.29e-61FFCP PHASE1:Hg19::chr1:211848955..211848981,-#_55ebf954411c5e3590431e6c5718d42ep1@NEK2
5.28e-61FFCP PHASE2:Hg19::chr11:125495862..125495882,+#_6db2b8a81d2606d8d1c7eb18db656dd9p1@CHEK1
5.28e-61FFCP PHASE1:Hg19::chr11:125495862..125495882,+#_6db2b8a81d2606d8d1c7eb18db656dd9p1@CHEK1
7.39e-61FFCP PHASE1:Hg19::chr3:172468505..172468582,+#_0a51a991cdcb04b9213caaba2b7b72fcp1@ECT2
7.39e-61FFCP PHASE2:Hg19::chr3:172468505..172468582,+#_0a51a991cdcb04b9213caaba2b7b72fcp1@ECT2
8.33e-61FFCP PHASE1:Hg19::chr8:124408652..124408712,-#_910322899ee4480b3c49d913830c6d24p1@ATAD2
8.33e-61FFCP PHASE2:Hg19::chr8:124408652..124408712,-#_910322899ee4480b3c49d913830c6d24p1@ATAD2
1.27e-60FFCP PHASE2:Hg19::chr2:29117521..29117569,+#_64f4da3726043135a9c247870059a8e9p1@WDR43
1.27e-60FFCP PHASE1:Hg19::chr2:29117521..29117569,+#_64f4da3726043135a9c247870059a8e9p1@WDR43
1.38e-60FFCP PHASE2:Hg19::chr5:34915805..34915847,+#_87c1e21836fb33ad0392b6676f0e5ea9p1@BRIX1
1.38e-60FFCP PHASE1:Hg19::chr5:34915805..34915847,+#_87c1e21836fb33ad0392b6676f0e5ea9p1@BRIX1
3.64e-60FFCP PHASE1:Hg19::chr12:4647995..4648087,+#_bfa05fff243916f14b76f9b3ebe4964fp1@RAD51AP1
3.64e-60FFCP PHASE2:Hg19::chr12:4647995..4648087,+#_bfa05fff243916f14b76f9b3ebe4964fp1@RAD51AP1
6.38e-60FFCP PHASE2:Hg19::chr5:37288836..37288849,-#_379afc32952c440daedee9ab8a43b0d4p@chr5:37288836..37288849, -
6.38e-60FFCP PHASE1:Hg19::chr5:37288836..37288849,-#_379afc32952c440daedee9ab8a43b0d4p@chr5:37288836..37288849, -
6.59e-60FFCP PHASE1:Hg19::chr18:19192235..19192337,+#_b0537247baae5a8b5d9b8a391b343bc8p1@SNRPD1
6.59e-60FFCP PHASE2:Hg19::chr18:19192235..19192337,+#_b0537247baae5a8b5d9b8a391b343bc8p1@SNRPD1
9.29e-60FFCP PHASE2:Hg19::chr17:38574125..38574168,-#_deefde0b09509b7eb9222d374525591cp1@TOP2A
9.29e-60FFCP PHASE1:Hg19::chr17:38574125..38574168,-#_deefde0b09509b7eb9222d374525591cp1@TOP2A
1.22e-59FFCP PHASE1:Hg19::chr12:118454500..118454585,+#_6594a4e91782575cdec14fc587839521p1@RFC5
1.22e-59FFCP PHASE2:Hg19::chr12:118454500..118454585,+#_6594a4e91782575cdec14fc587839521p1@RFC5
5.0e-59FFCP PHASE2:Hg19::chr1:242011485..242011542,+#_01cd82a4ff04243dd1a58255a3fc0604p1@EXO1
5.0e-59FFCP PHASE1:Hg19::chr1:242011485..242011542,+#_01cd82a4ff04243dd1a58255a3fc0604p1@EXO1
5.74e-59FFCP PHASE2:Hg19::chr10:96363899..96363904,+#_e2ea1dcd51a79f27c5592ae945ba90c6p@chr10:96363899..96363904, +
5.74e-59FFCP PHASE1:Hg19::chr10:96363899..96363904,+#_e2ea1dcd51a79f27c5592ae945ba90c6p@chr10:96363899..96363904, +
6.27e-59FFCP PHASE2:Hg19::chr2:70529150..70529179,-#_b4e146c193198b66bf1584befc644fe0p1@FAM136A
6.27e-59FFCP PHASE1:Hg19::chr2:70529150..70529179,-#_b4e146c193198b66bf1584befc644fe0p1@FAM136A
1.27e-58FFCP PHASE2:Hg19::chr1:68962744..68962772,-#_3e3c00fba71bb0907ec335fc081e8534p1@DEPDC1
1.27e-58FFCP PHASE1:Hg19::chr1:68962744..68962772,-#_3e3c00fba71bb0907ec335fc081e8534p1@DEPDC1
2.97e-58FFCP PHASE1:Hg19::chr17:48450575..48450618,+#_e3cf93f731114198b25cb6604bac8868p1@EME1
2.97e-58FFCP PHASE2:Hg19::chr17:48450575..48450618,+#_e3cf93f731114198b25cb6604bac8868p1@EME1
4.71e-58FFCP PHASE1:Hg19::chr15:69706740..69706754,+#_9a9211969399c3d0b7f056945977d0b2p2@KIF23
4.71e-58FFCP PHASE2:Hg19::chr15:69706740..69706754,+#_9a9211969399c3d0b7f056945977d0b2p2@KIF23
6.8e-58FFCP PHASE2:Hg19::chr8:130951991..130952083,-#_0a23ded3616b8deca1361a340cb522eap1@FAM49B
6.8e-58FFCP PHASE1:Hg19::chr8:130951991..130952083,-#_0a23ded3616b8deca1361a340cb522eap1@FAM49B
8.54e-58FFCP PHASE1:Hg19::chr15:40453204..40453304,+#_a575f01a1ceb5168d47d3cbd330a119cp1@BUB1B
8.54e-58FFCP PHASE2:Hg19::chr15:40453204..40453304,+#_a575f01a1ceb5168d47d3cbd330a119cp1@BUB1B
1.04e-57FFCP PHASE1:Hg19::chr15:91537809..91537824,-#_6934d8d7525ca60f3d6cb0e8c9a53e8bp2@PRC1
1.04e-57FFCP PHASE2:Hg19::chr15:91537809..91537824,-#_6934d8d7525ca60f3d6cb0e8c9a53e8bp2@PRC1
1.18e-57FFCP PHASE1:Hg19::chr4:154265825..154265875,+#_d1b65e826d76fd9ccd9b5af08a5a07b6p1@MND1
1.18e-57FFCP PHASE2:Hg19::chr4:154265825..154265875,+#_d1b65e826d76fd9ccd9b5af08a5a07b6p1@MND1
1.26e-57FFCP PHASE2:Hg19::chr6:20402102..20402152,+#_b206259f5808dace7a5798cbbd7f0cd1p1@E2F3
1.26e-57FFCP PHASE1:Hg19::chr6:20402102..20402152,+#_b206259f5808dace7a5798cbbd7f0cd1p1@E2F3
1.48e-57FFCP PHASE1:Hg19::chr15:89787185..89787263,+#_1cf2c5b6ec92d5789f8f59a692b36176p1@FANCI
1.48e-57FFCP PHASE2:Hg19::chr15:89787185..89787263,+#_1cf2c5b6ec92d5789f8f59a692b36176p1@FANCI
1.5e-57FFCP PHASE1:Hg19::chr15:41625060..41625088,+#_0822cabe7edd262b8dce919eb11b5e89p1@NUSAP1
1.5e-57FFCP PHASE2:Hg19::chr15:41625060..41625088,+#_0822cabe7edd262b8dce919eb11b5e89p1@NUSAP1
3.35e-57FFCP PHASE1:Hg19::chr12:57146095..57146149,-#_37c03af3c00a63bd759dcab4fe369dc3p1@PRIM1
3.35e-57FFCP PHASE2:Hg19::chr12:57146095..57146149,-#_37c03af3c00a63bd759dcab4fe369dc3p1@PRIM1
3.45e-57FFCP PHASE2:Hg19::chr6:35888858..35888887,-#_0f79c51801e2eb66b80670eef562ebd2p1@SRPK1
3.45e-57FFCP PHASE1:Hg19::chr6:35888858..35888887,-#_0f79c51801e2eb66b80670eef562ebd2p1@SRPK1
3.55e-57FFCP PHASE1:Hg19::chr22:22901636..22901715,-#_9c40a5ddf8c0b2df2ec7eb2680c8873fp1@PRAME
3.55e-57FFCP PHASE2:Hg19::chr22:22901636..22901715,-#_9c40a5ddf8c0b2df2ec7eb2680c8873fp1@PRAME
3.96e-57FFCP PHASE1:Hg19::chr12:123237414..123237437,+#_29e038d6133ac3ba74a84690302b07b0p2@DENR
3.96e-57FFCP PHASE2:Hg19::chr12:123237414..123237437,+#_29e038d6133ac3ba74a84690302b07b0p2@DENR
4.25e-57FFCP PHASE2:Hg19::chr2:113522177..113522228,-#_cec2bf50f81af2163d87f1dacfbd1c33p1@CKAP2L
4.25e-57FFCP PHASE1:Hg19::chr2:113522177..113522228,-#_cec2bf50f81af2163d87f1dacfbd1c33p1@CKAP2L
4.48e-57FFCP PHASE2:Hg19::chr5:37371163..37371231,-#_358dfd10b2990d8be595d504e4644e05p1@NUP155
4.48e-57FFCP PHASE1:Hg19::chr5:37371163..37371231,-#_358dfd10b2990d8be595d504e4644e05p1@NUP155
4.86e-57FFCP PHASE2:Hg19::chr10:62538228..62538244,+#_6d0c388dc6d609503ec4421f48c31abcp1@CDK1
4.86e-57FFCP PHASE1:Hg19::chr10:62538228..62538244,+#_6d0c388dc6d609503ec4421f48c31abcp1@CDK1
4.99e-57FFCP PHASE1:Hg19::chr7:152373216..152373260,-#_66204e367bd5fb7178323b6528f597f3p1@XRCC2
4.99e-57FFCP PHASE2:Hg19::chr7:152373216..152373260,-#_66204e367bd5fb7178323b6528f597f3p1@XRCC2

Retrieved from "http://f5-webapp4.gsc.riken.jp/resource_browser/index.php?title=DOID:14566&oldid=3275630"